Effectiveness and safety of daily versus alternate-day rosuvastatin dose in dyslipidemic patients: a prospective, randomized and open-label study

Aishwarya Dafda; Navyug Raj Singh; Ajay Chhabra

doi:10.18203/2319-2003.ijbcp20243835

Authors

Aishwarya Dafda Department of Pharmacology, Government Medical College, Amritsar, Punjab, India
Navyug Raj Singh Department of Pharmacology, Government Medical College, Amritsar, Punjab, India
Ajay Chhabra Department of Medicine, Government Medical College, Amritsar, Punjab, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20243835

Keywords:

Dyslipidemia, Statins, Rosuvastatin, Lipid profile

Abstract

Background: Dyslipidemia is considered to be an important risk factor for development of atherosclerotic cardiovascular disease (ASCVD). Statins, also called HMG CoA reductase inhibitors are considered to the most effective lipid lowering agents. This study assessed the effectiveness and safety of daily versus alternate day dosing regimens of rosuvastatin in dyslipidemia patients.

Methods: This study was conducted for a period of 12 weeks. Study subjects comprised patients of either sex in age group 18-65 years diagnosed with dyslipidemia and a total of 90 subjects completed study who were randomly distributed to three groups, A (rosuvastatin 10 mg daily), B (rosuvastatin 10 mg on alternate days) and C (rosuvastatin 20 mg on alternate days).

Results: Rosuvastain significantly lowered total cholesterol, low density lipoprotein-cholesterol and triglycerides in all groups (p<0.001). High density lipoprotein-cholesterol increased, but non-significantly (p>0.05). Intergroup differences were not statistically significant. Group A reported slightly more adverse events than group B and group C.

Conclusions: Alternate-day rosuvastatin therapy showed effectiveness statistically similar to the daily dose therapy in dyslipidemic individuals. It also exhibited fewer side effects, suggesting it could be a feasible approach for managing dyslipidemia, providing a more economical and potentially safer alternative to daily administration.

Metrics

Metrics Loading ...

References

Talpur MT, Katbar MT, Shabir KU, Shabir KU, Yaqoob U, Jabeen S, et al. Prevalence of dyslipidemia in young adults. The Prof Med J. 2020;27(05):987-93.

Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care: Clinics in Office Practice. 2013;40(1):195-211.

García MJ, Reinoso RF, Sánchez Navarro A, Prous JR. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol. 2003;25(6):457-81.

Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007;67(1):121-53.

Bełtowski J, Wójcicka G, Jamroz-Wiśniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf. 2009;4(3):209-28.

Juszczyk MA, Seip RL, Thompson PD. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol. 2005;8(4):197-9.

Vasa M, Polasani MR, Mala RD, Yadav A, Venkatrao PB. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol. 2023;13(1):21-6.

Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M. Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther. 2003;8(2):123-6.

Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. Cardiovasc Drugs Ther. 2017;31(2):179-86.

Harivenkatesh N, David DC, Haribalaji N, Sudhakar MK. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial. J Cardiovascular Pharmacol Therapeut. 2014;19(3):296-303.

Panchavarthi C, Shankara UT, Pakanati V, Siddamshetty S, Konda JP. Efficacy of alternate day versus everyday dosing of rosuvastatin in hyperlipidemia. Int J Basic Clin Pharmacol. 2017;5(5):2045-50.

Dulay D, LaHaye SA, Lahey KA, Day AG. Efficacy of alternate day versus daily dosing of rosuvastatin. Can J Cardiol. 2009;25(2):e28-31.

Wongwiwatthananukit S, Sansanayudh N, Dhummauppakorn R, Kitiyadisai C. Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia. Ann Pharmacother. 2006;40(11):1917-23.

Ghia CJ, Panda AS, Khobragade LR, Jha RK, Rambhad GS. Alternate Day versus Once Daily Atorvastatin for Primary Prevention of (CHD) in Naïve Patients of Dyslipidemia. J Clin Diagn Res. 2014;8(3):27-31.

Awad K, Mikhailidis DP, Toth PP, Jones SR, Moriarty P, Lip GYH, et al. Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2017;31(4):419-31.